6.
Mitsumori K, Koizumi H, Nomura T, Yamamoto S
. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. Toxicol Pathol. 1998; 26(4):520-31.
DOI: 10.1177/019262339802600408.
View
7.
Saitoh A, Kimura M, Takahashi R, Yokoyama M, Nomura T, Izawa M
. Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene. 1990; 5(8):1195-200.
View
8.
Pettan-Brewer C, Treuting P
. Practical pathology of aging mice. Pathobiol Aging Age Relat Dis. 2012; 1.
PMC: 3417704.
DOI: 10.3402/pba.v1i0.7202.
View
9.
Morton D, Alden C, Roth A, Usui T
. The Tg rasH2 mouse in cancer hazard identification. Toxicol Pathol. 2002; 30(1):139-46.
DOI: 10.1080/01926230252824851.
View
10.
Boyle M, Paranjpe M, Creasy D
. High Background Incidence of Spontaneous Subcapsular Adrenal Gland Hyperplasia of Tg.rasH2 Mice Used in 26-week Carcinogenicity Studies. Toxicol Pathol. 2018; 46(4):444-448.
DOI: 10.1177/0192623318770965.
View
11.
Tsuchiya T, Kobayashi K, Sakairi T, Goto K, Okada M, Sano F
. Skeletal myopathy in transgenic mice carrying human prototype c-Ha-ras gene. Toxicol Pathol. 2002; 30(4):501-6.
DOI: 10.1080/01926230290105677.
View
12.
Paranjpe M, Belich J, Mann P, McKeon M, Elbekai R, Brown C
. A Comparison of Spontaneous Tumors in Tg.rasH2 Mice in 26-week Carcinogenicity Studies Conducted at a Single Test Facility during 2004 to 2012 and 2013 to 2018. Toxicol Pathol. 2018; 47(1):18-25.
DOI: 10.1177/0192623318810202.
View
13.
Takaoka M, Sehata S, Maejima T, Imai T, Torii M, Satoh H
. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice. Toxicol Pathol. 2003; 31(2):191-9.
DOI: 10.1080/01926230390183670.
View
14.
Tamaoki N
. The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis. Toxicol Pathol. 2001; 29 Suppl:81-9.
DOI: 10.1080/019262301753178492.
View
15.
Cora M, Kooistra L, Travlos G
. Vaginal Cytology of the Laboratory Rat and Mouse: Review and Criteria for the Staging of the Estrous Cycle Using Stained Vaginal Smears. Toxicol Pathol. 2015; 43(6):776-93.
PMC: 11504324.
DOI: 10.1177/0192623315570339.
View
16.
Paranjpe M, Belich J, Richardson D, Vidmar T, Mann P, McKeon M
. Progression of Serosal Vascular Proliferative Lesions to Hemangiosarcomas in the Uterus of the 26-Week Tg.rasH2 Mice Carcinogenicity Studies. Int J Toxicol. 2016; 36(1):29-34.
DOI: 10.1177/1091581816659068.
View
17.
MacDonald J, French J, Gerson R, Goodman J, Inoue T, Jacobs A
. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. Toxicol Sci. 2003; 77(2):188-94.
DOI: 10.1093/toxsci/kfh037.
View
18.
Nambiar P, Turnquist S, Morton D
. Spontaneous tumor incidence in rasH2 mice: review of internal data and published literature. Toxicol Pathol. 2012; 40(4):614-23.
DOI: 10.1177/0192623311436181.
View
19.
Cooper T, Meyerholz D, Beck A, Delaney M, Piersigilli A, Southard T
. Research-Relevant Conditions and Pathology of Laboratory Mice, Rats, Gerbils, Guinea Pigs, Hamsters, Naked Mole Rats, and Rabbits. ILAR J. 2022; 62(1-2):77-132.
PMC: 9291387.
DOI: 10.1093/ilar/ilab022.
View
20.
Paranjpe M, Elbekaei R, Shah S, Hickman M, Wenk M, Zahalka E
. Historical control data of spontaneous tumors in transgenic CByB6F1-Tg(HRAS)2Jic (Tg.rasH2) mice. Int J Toxicol. 2013; 32(1):48-57.
DOI: 10.1177/1091581812471565.
View